Tipranks Press Release.
BOSTON (AP) — BOSTON (AP) — Haemonetics Corp. (HAE) on Thursday reported fiscal second-quarter profit of $46.
Medical stock Haemonetics is near a buy point ahead of earnings on Nov. 5 after securing the FDA's approval for its vascular closure system.
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. Read more here.
Haemonetics Corporation is downgraded to Hold after a sharp share price surge and expanded CSL Plasma agreement. Read more on HAE stock here.
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Haemonetics (HAE) surged 17% to a 52-week high after a CSL plasma supply deal.
Haemonetics stock hits a new 52-week high after CSL Plasma outlines a sweeping rollout of its technology across existing U.S. centers.
These are the stocks posting the largest moves premarket.
Haemonetics (NYSE:HAE) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Haemonetics (HAE) has been drawing investor attention after a strong total return over the past year, along with double-digit annual growth in both revenue and net income. Despite a small dip in the latest session, Haemonetics’ share price is US$108.52, with a strong 90 day share price return of 48.92% and a 1 year total shareholder return of 114.25%. This points to momentum building as investors reassess growth prospects and risk. Scan Haemonetics’ momentum against peers and uncover other...
This is the newest page. Registered accounts read further back.